Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy
International Journal of Clinical Oncology, 06/26/2012
Yamada T et al. – The genetic backgrounds for CYP17A1 genes could influence the progression of prostate cancer to castration–resistant prostate cancer (CRPC) after androgen deprivation therapy.
Methods- Two hundred and fourteen Japanese patients with prostate cancer who were receiving androgen deprivation therapy were enrolled in this study.
- The authors investigated 22 single-nucleotide polymorphisms (SNPs) from 8 genes related to steroidogenesis.
- The SNPs were assayed by polymerase chain reaction (PCR)-based methods.
- The different genotypes in this cohort were analyzed according to a case–control status of progression to CRPC at the median duration of hormonal therapy.
- A logistic regression method with adjustments for patients’ characteristics was applied for the analysis.
- After applying the logistic regression method, they performed Cox regression analysis, following Kaplan–Meier and log-rank analyses.
- In the logistic regression analysis four genetic polymorphisms, rs743572, rs6162, rs6163, and rs1004467, in the CYP17A1 gene were significantly associated with a risk of progression to CRPC (p<0.05).
- Cox regression analysis for these SNPs showed an association of risk of progression to CRPC with the rs743572 genotype (p=0.02, odds ratio [OR] 0.43, 95 % confidence interval [CI] 0.22–0.85).
